Inovio Pharmaceuticals (INO) Competitors $2.44 -0.03 (-1.21%) Closing price 04:00 PM EasternExtended Trading$2.46 +0.02 (+0.82%) As of 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock INO vs. MRNA, KIDS, CBLL, SMLR, TMCI, DCTH, DRTS, NPCE, RXST, and CARLShould you be buying Inovio Pharmaceuticals stock or one of its competitors? The main competitors of Inovio Pharmaceuticals include Moderna (MRNA), OrthoPediatrics (KIDS), CeriBell (CBLL), Semler Scientific (SMLR), Treace Medical Concepts (TMCI), Delcath Systems (DCTH), Alpha Tau Medical (DRTS), NeuroPace (NPCE), RxSight (RXST), and Carlsmed (CARL). Inovio Pharmaceuticals vs. Its Competitors Moderna OrthoPediatrics CeriBell Semler Scientific Treace Medical Concepts Delcath Systems Alpha Tau Medical NeuroPace RxSight Carlsmed Inovio Pharmaceuticals (NASDAQ:INO) and Moderna (NASDAQ:MRNA) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, institutional ownership, media sentiment, risk, valuation, earnings and dividends. Does the media favor INO or MRNA? In the previous week, Moderna had 15 more articles in the media than Inovio Pharmaceuticals. MarketBeat recorded 18 mentions for Moderna and 3 mentions for Inovio Pharmaceuticals. Inovio Pharmaceuticals' average media sentiment score of 0.91 beat Moderna's score of 0.43 indicating that Inovio Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Inovio Pharmaceuticals 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Moderna 5 Very Positive mention(s) 2 Positive mention(s) 7 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Do analysts prefer INO or MRNA? Inovio Pharmaceuticals currently has a consensus price target of $8.80, indicating a potential upside of 260.66%. Moderna has a consensus price target of $41.81, indicating a potential upside of 59.29%. Given Inovio Pharmaceuticals' stronger consensus rating and higher possible upside, research analysts plainly believe Inovio Pharmaceuticals is more favorable than Moderna.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Inovio Pharmaceuticals 1 Sell rating(s) 3 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.29Moderna 5 Sell rating(s) 14 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 2.00 Which has higher earnings & valuation, INO or MRNA? Inovio Pharmaceuticals has higher earnings, but lower revenue than Moderna. Moderna is trading at a lower price-to-earnings ratio than Inovio Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioInovio Pharmaceuticals$220K589.37-$107.25M-$2.61-0.93Moderna$3.24B3.17-$3.56B-$7.53-3.49 Which has more risk and volatility, INO or MRNA? Inovio Pharmaceuticals has a beta of 1.65, meaning that its stock price is 65% more volatile than the S&P 500. Comparatively, Moderna has a beta of 2.01, meaning that its stock price is 101% more volatile than the S&P 500. Do insiders & institutionals believe in INO or MRNA? 26.8% of Inovio Pharmaceuticals shares are held by institutional investors. Comparatively, 75.3% of Moderna shares are held by institutional investors. 2.3% of Inovio Pharmaceuticals shares are held by insiders. Comparatively, 11.0% of Moderna shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth. Is INO or MRNA more profitable? Inovio Pharmaceuticals has a net margin of 0.00% compared to Moderna's net margin of -94.31%. Moderna's return on equity of -25.96% beat Inovio Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Inovio PharmaceuticalsN/A -163.32% -96.41% Moderna -94.31%-25.96%-20.09% SummaryModerna beats Inovio Pharmaceuticals on 8 of the 15 factors compared between the two stocks. Get Inovio Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for INO and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding INO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart INO vs. The Competition Export to ExcelMetricInovio PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$131.26M$3.36B$6.02B$10.45BDividend YieldN/A2.31%5.73%4.82%P/E Ratio-0.9322.0385.1227.24Price / Sales589.37472.74589.92133.47Price / CashN/A44.9825.7730.18Price / Book1.2810.4312.676.76Net Income-$107.25M-$52.58M$3.32B$276.59M7 Day Performance2.09%0.98%0.50%0.86%1 Month Performance2.52%14.76%9.42%8.17%1 Year Performance-57.19%21.29%79.11%43.66% Inovio Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)INOInovio Pharmaceuticals3.8129 of 5 stars$2.44-1.2%$8.80+260.7%-57.0%$131.26M$220K-0.93320Gap DownMRNAModerna4.2682 of 5 stars$28.49+0.4%$41.81+46.8%-54.1%$11.08B$3.24B-3.785,800KIDSOrthoPediatrics4.6286 of 5 stars$18.77+4.7%$34.14+81.9%-28.9%$470.56M$204.73M-10.49200Positive NewsAnalyst DowngradeHigh Trading VolumeCBLLCeriBell2.2425 of 5 stars$12.64+7.0%$32.14+154.3%N/A$463.38M$65.44M-4.23N/APositive NewsHigh Trading VolumeSMLRSemler Scientific3.2308 of 5 stars$30.56-2.6%$74.25+143.0%-4.1%$452.59M$56.29M12.58120Gap DownTMCITreace Medical Concepts2.1537 of 5 stars$6.36+1.6%$9.83+54.6%+14.1%$401.76M$209.36M-8.05250Gap UpDCTHDelcath Systems2.5834 of 5 stars$11.10+4.2%$24.50+120.7%+36.3%$388.28M$37.21M222.0060Analyst DowngradeDRTSAlpha Tau Medical2.0905 of 5 stars$4.31-2.0%$9.00+108.8%+78.6%$365.57MN/A-8.9880NPCENeuroPace3.6728 of 5 stars$10.92+4.7%$16.60+52.0%+58.5%$361.23M$79.91M-13.00170News CoverageRXSTRxSight2.8282 of 5 stars$8.80+2.8%$10.00+13.6%-84.9%$360.06M$147.06M-11.00220CARLCarlsmedN/A$12.97-2.7%N/AN/A$344.76M$38.27M0.00100Gap Down Related Companies and Tools Related Companies Moderna Alternatives OrthoPediatrics Alternatives CeriBell Alternatives Semler Scientific Alternatives Treace Medical Concepts Alternatives Delcath Systems Alternatives Alpha Tau Medical Alternatives NeuroPace Alternatives RxSight Alternatives Carlsmed Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:INO) was last updated on 10/14/2025 by MarketBeat.com Staff From Our PartnersURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredClaim Your Share of $5.39 BILLION in AI Equity ChecksThe U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | SponsoredREVEALED: Something Big Happening Behind White House DoorsWhat I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | Sponsored$3,600 gold is nice ... but here’s what most gold bugs are missingGold just surged past $3,600, but Weiss Ratings expert Sean Brodrick says the real upside is in select gold st...Weiss Ratings | SponsoredBuy this stock before Tesla’s November 6 announcementThe End of Tesla? "Hold onto your Tesla stock." That's the message insiders at Tesla have been giving staff...Altimetry | SponsoredGold to $27,533?This week, U.S. gold reserves hit an unprecedented $1 TRILLION in value... And it's sparking urgent chatter...Stansberry Research | SponsoredOptions Pro Reveals His #1 Retirement Income TradeIf you want a way to generate consistent market income without chasing volatile AI stocks or complex crypto tr...Base Camp Trading | SponsoredWhat the hell is going on, America?America’s $37.5 trillion debt spiral, soaring deficits, and repeated credit downgrades are exactly what Porter...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Inovio Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Inovio Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
